戻る Agenda
ATMP Regulation 2.0 – Is the System Fit as is?
Session Chair(s)
Ana Hidalgo-Simon, DrMed
Head of Advanced Therapies
European Medicines Agency, Netherlands
In this session we will look at the specificities of ATMPs and the needs of their developers. We will explore the current regulatory framework flexibility to be fit for purpose – its ups and downs.
Learning Objective : - Understand how current regulation is applied to ATMPs in the EU - Identify main regulatory challenges and how they can be addressed when developing ATMPs - Present practical examples of good and bad fits aspects of the current regulation for ATMPs development, from different stakeholders’ points of view - Design successful plans for multipurpose (including regulatory) evidence generation
Speaker(s)
Challenges and Opportunities Regarding Regulatory/ Environmental Framework with GMO Containing IMPs - an Industry Perspective
Myra Widjojoatmodjo, PhD
Janssen Vaccines & Prevention B.V., Netherlands
Director
The RSS and the future of ATMP development in Europe – regulator perspective
Nuria Semis-Costa, MSc
European Medicines Agency, Netherlands
Scientific Specialist (Risk Management)
Early Development of ATMPs by Academic Institutions – Academic Perspective
Pauline Meij
Department of Clinical Pharmacy and Toxicology, Leiden Univ, Netherlands
Head of Production ATMP / Qualified Person